Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but 36 and >18 months, respectively). In addition, two patients had partial responses (PR), one still ongoing (>42 months) with only a small bone-lesion remaining, and one of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lövgren, Tanja, Wolodarski, Maria, Wickstrom, Stina, Edback, Ulrika, Wallin, Mette, Martell, Eva, Markland, Katrin, Blomberg, Pontus, Nystrom, Maria, Lundqvist, Andreas, Jacobsson, Hans, Ullenhag, Gustav, Ljungman, Per, Hansson, Johan, Masucci, Giuseppe, Tell, Roger, Poschke, Isabel, Adamson, Lars, Mattsson, Jonas, Kiessling, Rolf
Format: Artikel
Sprache:eng
Schlagworte:
adoptive tumor-infiltrating lymphocyte therapy
Cancer and Oncology
Cancer och onkologi
Combination immunotherapy
DC vaccination
immune checkpoint inhibitor resistance
tumor lysate
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but 36 and >18 months, respectively). In addition, two patients had partial responses (PR), one still ongoing (>42 months) with only a small bone-lesion remaining, and one of short duration (
DOI:10.1080/2162402X.2020.1792058